Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Apr;16(3):541-543.
doi: 10.1007/s11739-021-02659-2. Epub 2021 Feb 12.

Procalcitonin in daily clinical practice: an evergreen tool also during a pandemic

Alessandro Russo  1 , Mario Venditti  2 , Giancarlo Ceccarelli  2 , Claudio Maria Mastroianni  2 , Gabriella d'Ettorre  2
Affiliations
Comment

Procalcitonin in daily clinical practice: an evergreen tool also during a pandemic

Alessandro Russo et al. Intern Emerg Med. 2021 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Management of COVID-19 patients at emergency department and during hospitalization
See this image and copyright information in PMC

Comment on

References

    1. Hamade B, Huang DT. Procalcitonin: where are we now? Crit Care Clin. 2020;36:23–40. doi: 10.1016/j.ccc.2019.08.003. - DOI - PMC - PubMed
    1. Bassetti M, Russo A, Righi E, Dolso E, Merelli M, et al. Role of procalcitonin in bacteremic patients and its potential use in predicting infection etiology. Expert Rev Anti Infect Ther. 2019;17:99–105. doi: 10.1080/14787210.2019.1562335. - DOI - PubMed
    1. Bassetti M, Russo A, Righi E, Dolso E, Merelli M, et al. Role of procalcitonin in predicting etiology in bacteremic patients: report from a large single-center experience. J Infect Public Health. 2020;13:40–45. doi: 10.1016/j.jiph.2019.06.003. - DOI - PubMed
    1. Johnson SA, Rupp AB, Rupp KL, et al. Clinical outcomes and costs associated with procalcitonin utilization in hospitalized patients with pneumonia, heart failure, viral respiratory infection, or chronic obstructive pulmonary disease. Intern Emerg Med. 2021 doi: 10.1007/s11739-020-02618-3. - DOI - PubMed
    1. Russo A, Bellelli V, Ceccarelli G, Marincola Cattaneo F, Bianchi L, Pierro R, Russo R, Steffanina A, Pugliese F, Mastroianni CM, d’Ettorre G, Sabetta F. Comparison between hospitalized patients affected or not by COVID-19 (RESILIENCY study) Clin Infect Dis. 2020;18:ciaa11745. doi: 10.1093/cid/ciaa1745. - DOI - PMC - PubMed

LinkOut - more resources